Cochrane for Clinicians
Putting Evidence into Practice
Capsaicin for Nonallergic Rhinitis
Am Fam Physician. 2016 Aug 1;94(3):217-218.
Is intranasal capsaicin effective for nonallergic rhinitis?
Intranasal capsaicin is safe and effective for reducing symptoms of nonallergic rhinitis (number needed to treat = 4; 95% confidence interval [CI], 1 to 22). There is insufficient evidence to compare the effectiveness of capsaicin to other topical or systemic medications. (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)
Nonallergic rhinitis is a broad term used to describe a heterogeneous group of sinus diseases that are not triggered by aeroallergens.1 The prevalence of nonallergic rhinitis is 5% to 10% worldwide,2 and symptoms include nasal congestion, blockage or obstruction, sneezing, clear rhinorrhea, and nasal itching. Nonallergic rhinitis is diagnosed by exclusion of symptoms related to aeroallergen exposure or infection and anatomic abnormalities through the history and physical examination.3 The authors of this Cochrane review evaluated the effectiveness of intranasal capsaicin in the management of nonallergic rhinitis.
This Cochrane review included two randomized controlled trials (RCTs) and two quasi-RCTs with a total of 302 participants 16 to 65 years of age with nonallergic rhinitis. They all had symptoms lasting at least one hour per day for at least five days during the two weeks preceding the study. Patients with allergic rhinitis, acute or chronic rhinosinusitis, autoimmune rhinitis, or rhinitis related to anatomic abnormalities were excluded. Nasal capsaicin was used in total daily dosages of 42 to 107 mcg given during various treatment periods of three days to four weeks. The primary outcomes were overall symptom scores (global symptom scores, daily record chart score), individual symptom scores (nasal congestion, rhinorrhea, sneezing, nasal itching), and adverse effects. The risk of bias in these studies was low to unclear.
Overall, the results support the use of intranasal capsaicin as an effective way to manage nonallergic rhinitis. In one RCT (n = 24), patients received capsaicin (30 mcg) or placebo every two to three days for a total of seven treatments in two weeks. Capsaicin use improved overall nasal symptoms on a 10-point visual analogue scale during week 2 (mean difference [MD] vs. placebo = −3.34; 95% CI, −5.24 to −1.44); week 12 (MD = −3.73; 95% CI, −5.45 to −2.01); and week 36 (MD = −3.52; 95% CI, −5.55 to −1.48) posttreatment. Another study compared different dosages of capsaicin (1 mcg, 2 mcg, and 4 mcg three times per day for three consecutive days) and showed that at four weeks post-treatment, only the 4-mcg dosage was more effective than placebo for resolution of nasal symptoms (relative risk = 3.17; 95% CI, 1.38 to 7.29).
A third study comparing two treatment regimens of capsaicin (in each regimen the participants used a total of 82.5 mcg) reported that five treatments in one day was more effective in improving rhinorrhea than five treatments every two to three days over two weeks; numerical data were not provided. An RCT of 40 patients showed that although there was no improvement in individual symptom score with capsaicin in a dosage of 10.5 mcg once weekly for four weeks vs. intranasal budesonide (Rhinocort), capsaicin use did improve aggregate symptom relief scores at four weeks on a 10-point visual analogue scale (MD = 2.50; 95% CI, 1.06 to 3.94). Study heterogeneity precluded meta-analysis.
Only one study measured adverse effects. These included nasal blockage, itching, sneezing, and coughing, which are also symptoms of nonallergic rhinitis. Because the study did not clarify when these symptoms were measured, no definitive conclusions could be drawn. Intranasal capsaicin has been reported to cause burning, lacrimation, rhinorrhea, and cough.4
Capsaicin is available over the counter as an inexpensive nasal spray. Clinical guidelines from the National Asthma Council Australia and The British Society for Allergy and Clinical Immunology support the use of capsaicin for nonallergic rhinitis as a complementary treatment.5,6
SOURCE: Gevorgyan A, Segboer C, Gorissen R, van Drunen CM, Fokkens W. Capsaicin for non-allergic rhinitis. Cochrane Database Syst Rev. 2015;(7):CD010591.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD010591.
REFERENCESshow all references
1. Lieberman P, Pattanaik D. Nonallergic rhinitis. Curr Allergy Asthma Rep. 2014;14(6):439....
2. Van Gerven L, Alpizar YA, Wouters MM, et al. Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. J Allergy Clin Immunol. 2014;133(5):1332–1339.
3. van Rijswijk JB, Gerth van Wijk R. Capsaicin treatment of idiopathic rhinitis: the new panacea? Curr Allergy Asthma Rep. 2006;6(2):132–137.
4. Kushnir NM. The role of decongestants, cromolyn, guafenesin, saline washes, capsaicin, leukotriene antagonists, and other treatments on rhinitis. Immunol Allergy Clin North Am. 2011;31(3):601–617.
5. National Asthma Counsel Australia. Managing allergic rhinitis in people with asthma. 2012. http://www.nationalasthma.org.au/uploads/publication/allergic-rhinitis-asthma-hp.pdf. Accessed November 22, 2015.
6. Scadding GK, Durham SR, Mirakian R, et al.; British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19–42.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Nov 1, 2020
Access the latest issue of American Family Physician